Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens

NCT ID: NCT00760487

Last Updated: 2012-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31

Brief Summary

The purpose of this study is to evaluate the effect that placement and power of the AcrySof Toric has on post-operative visual acuity and spectacle independence for distance vision. This will be determined by comparing manifest refraction pre-operatively and post-operatively and by evaluating the rotational stability of the lens over time.

Conditions

Cataract

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AcrySof Toric IOL

AcrySof Toric Intraocular Lens (IOL)

Group Type: EXPERIMENTAL

AcrySof Toric IOL

Intervention Type: DEVICE

Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments

Interventions

AcrySof Toric IOL

Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Are a candidate for bilateral implantation
• In good general and ocular health, 21 years of age or older, of either gender or any race, diagnosed with age-related cataracts in both eyes
• In need of spherical correction between 10.0 Diopter (D) and 30.0 D
• Preoperative regular corneal astigmatism, ≥ 1.0 D and ≤ 2.5 D , as measured by keratometry
• Willing and able to complete all required postoperative visits
• Able to comprehend and sign a statement of informed consent
• Pupil dilation ≥ 6.0 mm
• Expected to achieve a postoperative logMAR +0.3 or better visual acuity (as assessed by one or more of the following: fundus examination, pinhole visual acuity, and/or PAM evaluation);

Exclusion Criteria

• Previous cataract patient without potential of bilateral implantation
• Females of child bearing potential
• Irregular corneal astigmatism
• Keratopathy/Keratectasia - any corneal abnormality including but not limited to the following: keratoconus, keratoglobus, keratolysis, keratomalacia, keratomycosis, and cornea plana
• Any inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis
• Previous corneal reshaping, including but not limited to the following: keratomileusis, radial keratotomy (RK), photorefractive keratectomy (PRK), Laser in Situ Keratomileusis (LASIK), Thermal Keratoplasty (TK), and Penetrating Keratoplasty (PK)
• Clinically significant corneal dystrophy (including Fuch's dystrophy)
• Previous corneal transplant
• Amblyopia
• Glaucoma (medically uncontrolled)
• Clinically significant RPE/Macular changes
• Proliferative diabetic retinopathy
• History of macular edema
• Previous history of retinal detachment
• History of uveitis/iritis
• Extremely shallow anterior chamber, not due to swollen cataract
• Iris neovascularization
• Microphthalmos
• Absent eye or eye with no light perception (NLP) as fellow eye
• Rubella, congenital, traumatic, or complicated cataract
• Optic atrophy

• Other procedures at this surgery
• Limbal relaxing incisions (LRIs) or any other procedure to reduce the amount of preoperative astigmatism on the study eye(s), whether implanted with SA60TT or SA60AT, for the duration of the study

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alcon Research

INDUSTRY

Sponsor Role: lead

Responsible Party

Alcon Canada Inc.

Locations

Alcon Call Center

Fort Worth, Texas, United States

Countries

United States

Other Identifiers

ALCONsurtor001.06

Identifier Type: -

Identifier Source: org_study_id